[1]Eslam M, Sanyal A J, George J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology, 2020,158(7):1999-2014. [2]Mak L, Yuen M, Seto W. Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement". J Hepatol, 2020,73(6):1573-1574. [3]Vesa C M, Behl T, Nemeth S, et al. Prediction of NAFLD occurrence in prediabetes patients. Exp Ther Med, 2020,20(6):190. [4]Alejandra P D O, Julián M T, Ramos A, et al. Microbiota, fiber, and NAFLD: is there any connection? Nutrients, 2020,12(10):3100. [5]Jayakumar S, Loomba R. Review article: emerging role of the gut microbiome in the progression of non-alcoholic fatty liver disease and potential therapeutic implications. Aliment Pharmacol Ther, 2019,50(2):144-158. [6]Jiao H, Lim A S, Fazio Coles T E, et al. The effect of high-fat diet-induced metabolic disturbance on corneal neuroimmune features. Exp Eye Res, 2020,201:108298. [7]Lee H A, Cho J, Afinanisa Q, et al. Ganoderma lucidum extract reduces insulin resistance by enhancing AMPK activation in high-fat diet-induced obese mice. Nutrients, 2020,12(11):3338. [8]White J R, Nagarajan N, Pop M. Statistical methods for detecting differentially abundant features in clinical metagenomic samples. PLoS Comput Biol, 2009,5(4): e1000352. [9]Fraulob J C, Ogg-Diamantino R, Fernandes-Santos C, et al. A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. J Clin Biochem Nutr, 2010,46(3):212-223. [10] Schwimmer J B, Johnson J S, Angeles J E, et al. Microbiome signatures associated with steatohepatitis and moderate to severe fibrosis in children with non-alcoholic fatty liver disease. Gastroenterology, 2019,157(4):1109-1122. [11] Ghoshal U C, Goel A, Quigley E M M. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: an emerging paradigm. Indian J Gastroenterol, 2020,39(1):9-21. [12] Simoes I C M, Janikiewicz J, Bauer J, et al. Fat and sugar-a dangerous duet. A comparative review on metabolic remodeling in rodent models of non-alcoholic fatty liver disease. Nutrients, 2019,11(12):2871. [13] Gastaldelli A. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD? Clin Sci, 2017,131(22):2701-2704. [14] Turnbaugh P J, Ley R E, Mahowald M A, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature, 2006,444(7122):1027-1031. [15] Kim S, Lee Y, Kim Y, et al. Akkermansia muciniphila prevents fatty liver disease, decreases serum triglycerides, and maintains gut homeostasis. Appl Environ Microbiol, 2020,86(7):e03004-30019. [16] Zhang X, Shen D, Fang Z, et al. Human gut microbiota changes reveal the progression of glucose intolerance. PloS one, 2013,8(8):e71108. [17] Naito Y, Uchiyama K, Takagi T. A next-generation beneficial microbe: Akkermansia muciniphila. J Clin Biochem Nutr, 2018,63(1):33-35. [18] Shin N, Lee J, Lee H, et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut, 2014,63(5):727-735. [19] Wang P, Li D, Ke W, et al. Resveratrol-induced gut microbiota reduces obesity in high-fat diet-fed mice. Int J Obes, 2019,44(1):213-225. |